Halifax police warn about ‘dangerous drug' seized during traffic stop
Police in the Halifax area are warning the public about a 'dangerous drug combination' seized during a traffic stop in April.
Halifax Regional Police officers pulled over a suspected impaired driver near Sea King Drive and Albro Lake Road around 3:30 a.m. on April 20.
Police say they seized and searched the vehicle and found an 'unknown substance' inside.
The substance, described as a grainy powder grey/green in colour, was sent to Health Canada for identification.
This week, Health Canada confirmed metonitazene – a potent synthetic opioid – was detected in the substance, along with fentanyl, caffeine and dimethyl sulfone.
'This combination of drugs is dangerous and may put users more at risk of an overdose,' said Const. Martin Cromwell in a news release.
'Even handling these substances can be risky without taking proper precautions.'
Police are reminding the public that Naloxone can reverse an opioid overdose.
Naloxone kits are available free of charge through the Nova Scotia Health's Take Home Naloxone Program.
For more Nova Scotia news, visit our dedicated provincial page
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
40 minutes ago
- CTV News
‘Serious health risks': Health Canada warns against recreational use of laughing gas
Health Canada issues a warning for recreational use of laughing gas - nitrous oxide - over "serious health risks." (Pexels/Stephen Andrews) Health Canada is warning people not to inhale nitrous oxide, commonly known as laughing gas, recreationally due to 'serious health risks, including death.' The health agency is aware that some of these products – labelled 'whip cream chargers' in various flavours – are being sold online and in retail stores. Several unauthorized products have been seized by the agency with the help of border authorities, in order to stop unauthorized shipments from entering the country. 'Advertising and selling nitrous oxide products for inhalation to the public is strictly prohibited,' Health Canada said in a safety alert. Nitrous oxide is a drug that can only be administered by an authorized health-care professional for sedation and pain relief during medical and dental procedures, the health agency says. When inhaled – or 'huffed' – laughing gas can cause serious adverse effects like increased heart rate, loss of consciousness, low blood pressure and lack of oxygen in the body, or asphyxia. It can cause issues like anemia and vitamin B12 deficiency, as well as birth defects, blood clots in the limbs and lungs, and air leaks between the lungs and chest wall. Other potential heart impacts include palpitations, heart attack and stroke. Nitrous oxide can damage nerves and contribute to spinal cord degeneration, as well as impair bladder and bowel functions, coordination while walking and sensation in the limbs and extremities. Confusion and delusion, agitation, hallucinations, feelings of paranoia and depression may also occur, and among the most serious health effects are prolonged pain, permanent paralysis and even death. Health Canada says prolonged use of the drug could result in lasting neurological damage, even after the usage has been stopped. Additionally, it can also result in addiction and withdrawal symptoms. In the case of inhalation, the health agency has advised seeking immediate medical attention from a health-care provider. 'Health Canada strongly advises that consumers not inhale any nitrous oxide products for recreational purposes,' the notice reads.
CBC
an hour ago
- CBC
Manitoba plastic surgeon given suspension after professional misconduct involving 3 patients
A Manitoba plastic surgeon was suspended from practising medicine for six weeks and ordered to pay more than $34,000 after he admitted to displaying a lack of skill, knowledge and judgment during a number of surgical procedures involving three patients over more than a decade. During a March College of Physicians and Surgeons of Manitoba disciplinary hearing, Dr. Manfred Ziesmann pleaded guilty to professional misconduct while providing care to three patients who had post-surgery complications between 2012 and 2023. He admitted to displaying "a lack of knowledge, skill and judgment in the practice of medicine" in all three cases, including one in which he put the wrong implants into a woman's breasts, according to a May 25 written decision delivered by a three-person inquiry panel for the college. That decision said Ziesmann's actions had a particularly negative impact on that patient, who "has suffered significantly over the last few years" after surgery he performed on her in 2022. Ziesmann, who has been licensed as a plastic surgeon since 1987, began treating the woman in 2021, after an earlier surgery by another doctor left her right breast, which had an implant, larger than her left, which had no implant. On the day of her surgery, she signed a consent indicating a larger implant would be inserted in her right breast, and a smaller implant in the left. However, during the surgery, Ziesmann inserted the larger implant into the left breast and the smaller implant into the right breast, according to the decision. After the procedure, the woman experienced significant issues, but had difficulty getting followup care from Ziesmann and felt "her concerns [had] been disregarded," according to the panel's decision. She went to a hospital emergency room and was referred to the plastic surgeon resident on call, whose consultation report said the woman had complete necrosis on her nipples, with thick, black dead tissue. A different surgeon removed the implants Ziesmann had put in, but "there is little doubt that she will continue to be impacted for years to come," the panel's decision said. Ziesmann admitted to breaching the standards of medical practice after he failed to address the woman's symptoms in a timely manner, and "displaying a lack of empathy and compassion in communicating" with the patient, the decision said. Failed to remove patient's skin cancer The panel also reviewed the case of a patient Ziesmann performed surgery on after who developed basal cell carcinoma — a type of skin cancer — from excessive sun damage. She was referred to Ziesmann, who performed a procedure to remove the lesion in April 2023, the decision said. However, a pathology report noted that the part extracted didn't have a scar that had been visible in the biopsy. The patient had a second excision in August of that year, but after both procedures, a dermatologist determined the patient still had skin cancer. She was referred to a different surgeon for a third procedure. Ziesmann acknowledged that he "failed to appropriately address the … pathology report which indicated that the procedure may not have been successful," the panel's decision said, and to acknowledge the importance of a "heightened degree" of care in the second procedure, "particularly given the first procedure was not successful." He also acknowledged that he "did not document sufficient steps to identify the lesion" in August of 2023. The panel found other gaps in Ziesmann's record-keeping from the care he provided another patient, who complained about breast augmentation surgery in 2012 that resulted in a stitch abscess — an abscess that forms due to infection of sutures. The patient faced issues with wound healing, scarring and retained surgical drain from three other surgeries Ziesmann performed from 2014 to 2019. Ziesmann said the patient had multiple factors that put her at higher risk for infections and delayed healing, but some of that analysis was not documented in his chart notes, he told the panel. Ziesmann had a professional obligation to document the conversations he had with the patient on treatment options, but failed to do so, breaching various standards of medical practice over the 10 years he treated her, the decision said. Under a joint recommendation between Ziesmann and the College of Physicians and Surgeons, the surgeon was given a six-week suspension, which began on March 24. Following that, he was allowed to resume practising, but under "lengthy conditions" to maintain professional standards and public safety, the decision said. The doctor's practice was already subject to interim conditions at the time of the March hearing. The panel's decision said it was informed of six prior complaints in which he was "criticized and/or provided with advice or reminders" regarding obtaining informed consent from patients, his vigilance in followup care, and the accuracy and completeness of clinical documentation. The May decision also ordered him to pay the college $34,295.70 in costs. The joint recommendation acknowledged that Ziesmann's guilty plea spared the college from a full inquiry process, the decision said, but "acts not only as a specific deterrent to Dr. Ziesmann but also as a general deterrent in that it imposes serious punishment for serious misconduct," the decision said.
CBC
2 hours ago
- CBC
Seasonique birth control pills from Teva Canada recalled due to extra yellow tablets
Social Sharing Health Canada issued a recall notice on Friday for some Seasonique birth control products due to some packages containing the correct blue-green pills coming with extraneous yellow tablets. The agency says the recall is for the 0.01-milligram ethinyl estradiol, 0.03-milligram ethiny lestradiol and 0.15-milligram levonorgestrel Seasonique pills made by Teva Canada. Health Canada said those who find the yellow pills should not consume them and return the product to a pharmacy for a replacement or alternative, adding that those who can't return them right away should continue taking the regular blue-green tablets as instructed until they are able to return them. "If you took a yellow pill instead of a blue-green pill ... or if you are unsure, you should also use another method of non-hormonal back-up contraception (such as condoms) and consult with your health care professional," the agency said. Friday's contraceptive pill recall is the latest by Teva Canada. On Thursday, it recalled its Seasonale pills (0.15-milligram levonorgestrel and 0.03-milligram ethinyl estradiol) due to white placebo pills being found among the regular pink tablets. And in May, Teva Canada had to recall the same Seasonique tablets recalled on Friday due complaints that packages were missing some pills.
